缺血性脑卒中（IS）和阿尔茨海默病（AD）具有共同的病理特征，如β-淀粉样蛋白沉积、血管病变、氧化应激和神经炎症等，均会导致认知能力下降。髓样细胞触发受体2（TREM2）作为免疫相关受体，可以通过调节小胶质细胞的表型和功能来协调神经炎症，参与AD和IS的进程。蛇床子素、补脾醒神益智方、AL002、褪黑激素、羟基红花黄色素A等靶向TREM2免疫受体，对AD和IS等神经退行性疾病有疗效。就TREM2在AD和IS中的重要作用和以TREM2为靶点治疗AD和IS的相关药物进行综述，以期为退行性疾病、脑血管疾病等相关治疗药物的研发提供新思路。

Alzheimer's disease (AD) and Ischemic stroke (IS) have common pathological features, such as Aβ deposition, vascular lesions, oxidative stress and neuroinflammation, which can lead to cognitive decline. Triggering receptor expressed on myeloid cells 2 (TREM2), as an immune-related receptor, can coordinate neuroinflammation and participate in the process of AD and IS by regulating the phenotype and function of microglia. At present, many drugs, such as osthole, Bupi Xingshen Yizhi recipe, AL002, melatonin, hydroxysafflor yellow A, etc., target TREM2 immune receptors and have therapeutic effects on neurodegenerative diseases such as AD and IS. In this paper, the important role of TREM2 in AD and IS and the related drugs targeting TREM2 to treat AD and IS are reviewed, so as to provide new ideas for the research and development of related drugs such as degenerative diseases and cerebrovascular diseases.

天津市科学基金项目（21JCYBJC01260）